farglitazar has been researched along with oxazoles in 21 studies
| Studies (farglitazar) | Trials (farglitazar) | Recent Studies (post-2010) (farglitazar) | Studies (oxazoles) | Trials (oxazoles) | Recent Studies (post-2010) (oxazoles) |
|---|---|---|---|---|---|
| 35 | 3 | 5 | 9,281 | 366 | 2,561 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (80.95) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baer, PG; Brown, KK; Chen, L; Clifton, LG; McNulty, JA; Yang, B | 1 |
| DeGrazia, MJ; Heuvel, JP; Peterson, BR; Thompson, J | 1 |
| Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE | 1 |
| Baer, PG; Bennett, T; Brown, KK; Gardiner, SM; Nunez, DJ | 1 |
| Bonev, AD; Eckman, DM; Gomez, MF; Heppner, TJ; Nelson, MT; Petkov, GV | 1 |
| Balon, TW; Binz, JG; Brown, KK; Chen, L; Chen, Z; Clifton, LG; Grimes, AM; Harrington, WW; McNulty, JA; Stimpson, SA; Strum, JC; Yang, B | 1 |
| Brown, KK; Carrick, KM; Chen, L; Clifton, LG; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B | 1 |
| Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T | 1 |
| Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ | 1 |
| Adrogue, JV; Brown, KK; Burgmaier, M; Golfman, LS; Guthrie, PH; Sharma, S; Taegtmeyer, H; Van Arsdall, M; Wilson, CR; Young, ME | 1 |
| Carrick, KM; Clifton, LG; Lin, P; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B | 1 |
| Brown, KK; Carrick, K; Chen, L; Clifton, LG; Geske, R; Han, B; McNulty, JA; Pahel, G; Qian, Y; Stimpson, SA; Strum, J; Triantafillou, JA; Yang, B | 1 |
| Billin, AN; Buckholz, RG; Cobb, JE; Hoekstra, WJ; Iannone, MA; Lambert, MH; Leesnitzer, LM; Nolte, RT; Pearce, KH; Shearer, BG; Trump, RP; Willson, TM; Zhao, SM | 1 |
| Hong, G; Hughes, A; Lin, X; McCarthy, A; McCarthy, L; Mosteller, M; Sathe, G; Smart, D; Spraggs, C; Traini, C; Van Horn, S; Warren, L | 1 |
| Azukizawa, S; Kanda, M; Kasai, M; Kunishiro, K; Miike, T; Mukai, C; Shirahase, H; Takahashi, K | 1 |
| Ashton, TT; Baines, D; Bisi, J; Blazer-Yost, BL; Brown, KK; Harrington, W; Kalsi, K; Maurio, FP; Murray, D; Nofziger, C; Smith, CD; West, TA | 1 |
| Brigandi, R; Chuang, WL; Gardner, S; Goodman, Z; Husa, P; Jonas, M; Levine, R; Makhlouf, H; McHutchison, J; Patel, K; Rockey, D; Rodriguez-Torres, M; Schultz, M; Shiffman, M; Stancil, B; Theodore, D; Watson, H; Webster, A | 1 |
| Agostinucci, K; Colton, HM; Dunn, ME; Engle, SK; Gallacher, M; Gropp, KE; King, NM; Manfredi, TG; More, V; Powe, J; Rodriguez, LA; Serra, D; Shimpi, P; Vetter, FJ | 1 |
| Byrjalsen, I; Christiansen, C; Gardner, S; Goodman, Z; Henriksen, K; Karsdal, MA; Krag, A; Leeming, DJ; Nielsen, MJ; Patel, K; Schuppan, D | 1 |
| Campbell, JM; Facchine, KL; Johnson, BS; Joshi, BK; Kraft, ES; Long, S; O'Connell, TM; Paulus, IV; Reynolds, DW; Sides, SL; Wolters, AM | 1 |
3 trial(s) available for farglitazar and oxazoles
| Article | Year |
|---|---|
Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar.
Topics: Adult; Aged; Base Sequence; Diabetes Mellitus, Type 2; DNA Primers; Edema; Epithelial Sodium Channels; Female; Genes, Reporter; Genetic Variation; Humans; Male; Middle Aged; Oxazoles; Pharmacogenetics; Phenotype; PPAR gamma; Promoter Regions, Genetic; Risk Factors; Time Factors; Tyrosine | 2007 |
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Oxazoles; PPAR gamma; Tyrosine | 2010 |
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.
Topics: Biomarkers; Collagen Type III; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Oxazoles; Patient Selection; Quinazolines; Thiazolidinediones; Tyrosine | 2016 |
18 other study(ies) available for farglitazar and oxazoles
| Article | Year |
|---|---|
Non-thiazolidinedione insulin sensitiser shows promise.
Topics: Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Multicenter Studies as Topic; Oxazoles; Thiazoles; Tyrosine | 2000 |
Effects of a PPARgamma agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats.
Topics: Animals; Glomerular Filtration Rate; Hypoglycemic Agents; Male; Nitrates; Nitric Oxide; Nitrites; Oxazoles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Renal Plasma Flow, Effective; Transcription Factors; Tyrosine | 2003 |
Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays.
Topics: Animals; Binding, Competitive; Crystallography, X-Ray; Drug Evaluation, Preclinical; Fluorescence Polarization; Fluorescent Dyes; Ligands; Mice; Molecular Structure; Oxazoles; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors; Tyrosine | 2003 |
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine | 2004 |
Regional hemodynamic effects of the N-(2-benzoylphenyl)-L-tyrosine peroxisome proliferator-activated receptor-gamma ligand, GI 262570 [(S)-2-(2-benzoylphenylamino)-3-[4-[2-(5-methyl-2-phenyl-2-oxazol-4-yl)ethoxy]phenyl]propionic acid], in conscious rats.
Topics: Acetylcholine; Animals; Hemodynamics; Indans; Male; Methoxamine; Naphthyridines; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oxazoles; Phentolamine; Propanolamines; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tyrosine | 2004 |
Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.
Topics: Algorithms; Animals; Barium; Benzophenones; Blood Pressure; Calcium Channels; Electrophysiology; Female; Hypoglycemic Agents; In Vitro Techniques; Membrane Potentials; Mesenteric Arteries; Muscle Cells; Muscle Tonus; Muscle, Smooth, Vascular; Oxazoles; Patch-Clamp Techniques; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tyrosine; Vasodilation | 2005 |
GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats.
Topics: Actins; Aldosterone; Amiloride; Animals; Blood Volume; Diuretics; Electrolytes; Epithelial Cells; Epithelial Sodium Channels; Gene Expression; Kidney Medulla; Kidney Tubules, Distal; Male; Nephrons; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sodium; Sodium Channels; Tyrosine; Water | 2005 |
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
Topics: Adiponectin; Animals; Biomarkers; Carrier Proteins; Diabetes Mellitus; Fatty Acid-Binding Proteins; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Obesity; Oxazoles; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Thiazolidinediones; Tyrosine | 2004 |
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts | 2004 |
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine | 2005 |
Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.
Topics: Adaptation, Physiological; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Glucose; In Vitro Techniques; Insulin Resistance; Male; Myocardial Contraction; Myocardium; Oxazoles; PPAR gamma; Rats; Rats, Inbred Strains; Rats, Zucker; Signal Transduction; Transcriptional Activation; Triglycerides; Tyrosine | 2005 |
PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Diabetes Mellitus, Experimental; Diet; Dose-Response Relationship, Drug; Insulin; Insulin Resistance; Male; Mice; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Tyrosine; Vascular Endothelial Growth Factor A | 2005 |
Changes of skeletal muscle adiponectin content in diet-induced insulin resistant rats.
Topics: Adiponectin; Animals; Dietary Fats; Dietary Sucrose; Dose-Response Relationship, Drug; Insulin Resistance; Male; Muscle, Skeletal; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Tyrosine | 2006 |
Co-crystal structure guided array synthesis of PPARgamma inverse agonists.
Topics: Crystallization; Ligands; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Oxazoles; PPAR gamma; Tyrosine | 2007 |
Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPAR gamma agonists.
Topics: 3T3 Cells; Adipocytes; Animals; Blood Glucose; Cell Differentiation; Chemical Phenomena; Chemistry, Physical; Chromatography, Thin Layer; Cyclization; Hypoglycemic Agents; Hypolipidemic Agents; Indicators and Reagents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Inbred ICR; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Spectrophotometry, Infrared; Structure-Activity Relationship; Tetrahydroisoquinolines; Triglycerides; Tyrosine | 2008 |
PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.
Topics: Animals; Biological Transport; Cell Line; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Dogs; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Kidney; Ligands; Models, Animal; Oxazoles; Pioglitazone; PPAR gamma; RNA, Messenger; Signal Transduction; Thiazolidinediones; Tyrosine; Vasopressins | 2009 |
Serum Natriuretic Peptides as Differential Biomarkers Allowing for the Distinction between Physiologic and Pathologic Left Ventricular Hypertrophy.
Topics: Animals; Biomarkers; Cardiotoxicity; Diagnosis, Differential; Hypertrophy, Left Ventricular; Male; Natriuretic Peptides; Oxazoles; PPAR gamma; Rats, Sprague-Dawley; Swimming; Tyrosine; Ventricular Function, Left; Ventricular Remodeling | 2017 |
The Degradation Chemistry of Farglitazar and Elucidation of the Oxidative Degradation Mechanisms.
Topics: Chemistry, Pharmaceutical; Hot Temperature; Humidity; Hydrolysis; Light; Oxazoles; Oxidation-Reduction; Photochemical Processes; Tyrosine | 2017 |